化合物 T28775
| 中文名稱 | 化合物 T28775 |
|---|---|
| 中文同義詞 | 化合物 T28775;化合物 SIBRAFIBAN |
| 英文名稱 | Sibrafiban |
| 英文同義詞 | Sibrafiban;Acetic acid, 2-[[1-[(2S)-2-[[4-[(Z)-amino(hydroxyimino)methyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]-, ethyl ester;WBNUCLPUOSXSNJ-UHFFFAOYSA-N |
| CAS號(hào) | 172927-65-0 |
| 分子式 | C20H28N4O6 |
| 分子量 | 420.46 |
| EINECS號(hào) | |
| 相關(guān)類別 | |
| Mol文件 | 172927-65-0.mol |
| 結(jié)構(gòu)式 |  |
化合物 T28775 性質(zhì)
| 密度 | 1.33±0.1 g/cm3(Predicted) |
|---|---|
| 儲(chǔ)存條件 | Store at -20°C |
| 溶解度 | DMSO：33.33 mg/mL（79.27 mM；需要超聲波） |
| 形態(tài) | 固體 |
| 酸度系數(shù)(pKa) | 13.16±0.10(Predicted) |
| 顏色 | 白色至米白色 |
Glycoprotein IIb/IIIa receptor
The effects of site occupancy by Sibrafiban on platelet activation are assessed using P-selectin expression, fibrinogen binding and microaggregate formation. Sibrafiban inhibits ADP and TRAP-stimulated fibrinogen binding and microaggregate formation in a concentration-dependent manner, whereas P-selectin expression is relatively unaltered. A decrease in site occupancy from peak to trough of Sibrafiban does not result in increased activation of platelets.
The effects of Ro 44-3888 on the platelet aggregation response to ADP (17 μmol) and on cutaneous bleeding times is determined in 8 rhesus monkeys given Sibrafiban 0.25 mg/kg/day or 0.5 mg/kg/day orally for 8 days. The maximum inhibition of ex vivo platelet aggregation and prolongation of bleeding time by Ro 44-3888 are dose dependent.
安全信息
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-10309 | 化合物 T28775 Sibrafiban | 172927-65-0 | 1 mg | 950元 |
| 2026/06/05 | HY-10309 | 化合物 T28775 Sibrafiban | 172927-65-0 | 5 mg | 2400元 |